| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF01745251 |
| P698 | PubMed publication ID | 7962989 |
| P2093 | author name string | P Charbonneau | |
| P2860 | cites work | Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin | Q28259678 |
| Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents | Q33744238 | ||
| Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate | Q35343060 | ||
| Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam | Q35360429 | ||
| Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes | Q35575783 | ||
| Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli | Q35650267 | ||
| Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections | Q36758337 | ||
| New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases | Q37896178 | ||
| Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli | Q39815796 | ||
| Therapy of mixed anaerobic-aerobic infections. Lessons from studies of intra-abdominal sepsis | Q39821689 | ||
| Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens | Q39855592 | ||
| Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases | Q40283720 | ||
| Clavulanic Acid, a Novel Inhibitor of β-Lactamases | Q40619414 | ||
| Penetration of piperacillin into bronchial mucosa and sputum | Q41202241 | ||
| Early synergistic interaction between semisynthetic penicillins and aminoglycosidic aminocyclitols against Enterobacteriaceae | Q42929022 | ||
| Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria | Q43971053 | ||
| In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria | Q44309116 | ||
| Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors | Q44687154 | ||
| Antimicrobial resistance: implications for antibiotic use. | Q44693163 | ||
| Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases. | Q54301692 | ||
| Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates. | Q54315333 | ||
| Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). | Q54342222 | ||
| Carbapenems: special properties contributing to their activity. | Q54448572 | ||
| The frequency of bacterial pathogens in infections potentially preventable by antimicrobial prophylaxis. | Q54720260 | ||
| Aspiration pneumonia | Q68021123 | ||
| [Epidemiologic study of pathogens causing nosocomial infections] | Q68170184 | ||
| In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases | Q68459304 | ||
| A 10-year survey of clinically significant blood culture isolates and antibiotic susceptibilities from adult patients with hematological diseases at a major Swedish hospital | Q68568693 | ||
| Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains | Q69364580 | ||
| Evolution of beta-lactamase inhibitors | Q70145276 | ||
| Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study | Q72544894 | ||
| Therapy of soft tissue infections with piperacillin/tazobactam | Q72956634 | ||
| Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections | Q72956661 | ||
| The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia | Q72956667 | ||
| P921 | main subject | piperacillin/tazobactam | Q7197337 |
| P304 | page(s) | S43-8 | |
| P577 | publication date | 1994-07-01 | |
| P1433 | published in | Intensive Care Medicine | Q15749164 |
| P1476 | title | Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy. | |
| P478 | volume | 20 Suppl 3 |
| Q35650111 | Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics |
| Q34119921 | Enhanced killing of antibiotic-resistant bacteria enabled by massively parallel combinatorial genetics |
| Q92150103 | Interplay between β-lactamases and new β-lactamase inhibitors |
| Q33701687 | Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis |
| Q35891315 | Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates |
Search more.